ChromaDex Corp. (CDXC)

[someconcerns]

As summarized by MT newswire:

ChromaDex Shares Rally After COVID-19 Patients on Nutrient Recover Faster in Study
BY MT Newswires
— 3:12 PM ET 02/25/2021

03:12 PM EST, 02/25/2021 (MT Newswires) -- ChromaDex ( CDXC ) shares jumped more than 120% Thursday after a late-stage study showed that the addition of a nutritional protocol including nicotinamide riboside helped speed up the recovery of mild-to-moderate COVID-19 patients.

The nutritional addition reduced recovery time and improved liver health while lowering inflammation, according to the trial results published on medRxiv. ChromaDex ( CDXC
Loading... Loading...
) markets Tru Niagen, a cellular nutrient used to raise nicotinamide levels.

Separately, the company said it has raised $25 million after selling some 3.85 million shares to institutional investors at $6.50 each. It plans to use the proceeds to grow the Tru Niagen brand and for general corporate purposes.

Price: 22.55, Change: +12.81, Percent Change: +131.52